Taiwan Advance Bio-Pharmaceutical, Inc.

As of June 30, 2026, Taiwan Advance Bio-Pharmaceutical, Inc. carries a market capitalization of 909.00M, placing it among publicly traded companies globally. Its enterprise value stands at 1.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Taiwan Advance Bio-Pharmaceutical, Inc. has 90.00M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Taiwan Advance Bio-Pharmaceutical, Inc. maintains a current ratio of 0.98, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Taiwan Advance Bio-Pharmaceutical, Inc.'s stock has declined approximately 49.82% over the past 52 weeks. The 50-day moving average sits at 7.59, while the 200-day moving average is 9.79.

As of June 30, 2026, Taiwan Advance Bio-Pharmaceutical, Inc. holds 157.98M in cash and equivalents against 299.63M in total debt, resulting in a net debt position of 135.03M. Total book value stands at 268.46M, with working capital of -4.88M providing operational flexibility.

Taiwan Advance Bio-Pharmaceutical, Inc.'s most recent stock split took place on September 28, 2020 with a 549:554 split ratio.